To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
BioCryst Pharma secures $350m from Royalty Pharma, OMERS
BioCryst Pharmaceuticals, a Durham, North Carolina-based developer of small molecule medicines for rare diseases, has raised $350 million in royalty financing.
